Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Andy Rawstron, Nichola Webster, Surita Dalal, Ruth M de Tute, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen

Blood (2023) 142 (Supplement 1): 632.

https://doi.org/10.1182/blood-2023-187943

Published: 2023

Journal Articles

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Blood (2023) 142 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2023-180527

Published: 2023

Journal Articles

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Blood (2023) 142 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2023-188597

Published: 2023

Journal Articles

Telomere Length Predicts for Outcome to FCR Chemoimmunotherapy in CLL

Kevin Norris, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Andy Rawstron, BSc, PhD, Robert K. Hills, MA, DPhil, MSc, Duncan M Baird, PhD, Chris Pepper, BSc, PhD, Christopher Fegan, MD

Blood (2018) 132 (Supplement 1): 1854.

https://doi.org/10.1182/blood-2018-99-114448

Published: 2018

Journal Articles

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Andy Rawstron, PhD, Talha Munir, Kristian Brock, MSc, BSc, Nichola Webster, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Sophie Cramp, MSc, BSc, Rebecca Bishop, BSc, Surita Dalal, PhD, Ruth M De Tute, BSc,MSc, Oonagh Sheehy, Andrew Pettitt, FRCPath, PhD, Christopher P. Fox, MD PhD, Stephen Devereux, PhD, Christopher Fegan, MD, Donald MacDonald, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 181.

https://doi.org/10.1182/blood-2018-181

Published: 2018

Journal Articles

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Andy Rawstron, BSc, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Donald Macdonald, Christopher Fegan, MD, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, Piers E.M. Patten, BSc, MRCP, MRCPath, PhD, Stephen Devereux, PhD, Adrian Bloor, MA MB BChir PhDFCRP FRCPath, Christopher P. Fox, MD PhD, Francesco Forconi, MD DM, PhD FRCPath, Talha Munir

Blood (2018) 132 (Supplement 1): 182.

https://doi.org/10.1182/blood-2018-182

Published: 2018

Journal Articles

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Peter Hillmen, MBChB, PhD, Talha Munir, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz Vicente, MSc, Francesca Yates, PhD, Rebecca Bishop, BSc, Christopher Fegan, MD, Donald Macdonald, Alison McCaig, PhD, Anna Schuh, MD PhD, Andrew Pettitt, FRCPath, PhD, John G. Gribben, MDDSc FMedSci, Stephen Devereux, FRCP, FRCPath, PhD, Adrian Bloor, Christopher P Fox, MBChB PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2017) 130 (Supplement 1): 428.

https://doi.org/10.1182/blood.V130.Suppl_1.428.428

Published: 2017

Journal Articles

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

Ruth M de Tute, PhD FRCPath, David Cairns, BSc, MSc, PhD, Andy Rawstron, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, John R Jones, MD, Martin F Kaiser, MD, Anna Hockaday, Alina Striha, MSc, Rowena Henderson, PhD, Gordon Cook, PhD, Nigel H. Russell, Mark T Drayson, MD PhD, Matthew W Jenner, Walter M Gregory, PhD, Graham Jackson, MDPhD, Gareth J. Morgan, MD PhD, Roger G. Owen, MD

Blood (2017) 130 (Supplement 1): 904.

https://doi.org/10.1182/blood.V130.Suppl_1.904.904

Published: 2017

Journal Articles

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 3004.

https://doi.org/10.1182/blood.V130.Suppl_1.3004.3004

Published: 2017

Journal Articles

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

Talha Munir, Peter Hillmen, MBChB, PhD, Lucy McParland, Dena Cohen, Anna Hockaday, Jamie Oughton, Fabrizio Messina, David Phillips, Jeffrey R. Neilson, FRCP,FRCPath, Nicholas Pemberton, Shankara Paneesha, MD MRCP, FRCPath, Ben Kennedy, MBChB, FRCP, FRCPath, Andy Rawstron, PhD

Blood (2017) 130 (Supplement 1): 3013.

https://doi.org/10.1182/blood.V130.Suppl_1.3013.3013

Published: 2017

Journal Articles

The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)

Talha Munir, Peter Hillmen, MBChB, PhD, Andy Rawstron, PhD, Kristian Brock, MSc, BSc, Samuel Munoz-Vicente, Francesca Yates, PhD, Surita Dalal, PhD, Ruth M de Tute, PhD FRCPath, Chris P Fox, Donald Macdonald, Christopher Fegan, MD, Adrian Bloor, Anna Schuh, MD PhD, Gina Doody

Blood (2017) 130 (Supplement 1): 3014.

https://doi.org/10.1182/blood.V130.Suppl_1.3014.3014

Published: 2017

Journal Articles

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Oliver C Cohen, MBBS MRCP, Neil Rabin, Nicholas Counsell, Roger G Owen, MD PhD, Bilyana Popova, Oliver Schofield, Janet Lyons-Lewis, Andy Rawstron, Christopher Spence, Ruth Mary de Tute, PhD FRCPath, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Sally Moore, BSc, FRPATH, FRCP, MBBS, Paul Smith, PhD, Kwee L Yong

Blood (2016) 128 (22): 4508.

https://doi.org/10.1182/blood.V128.22.4508.4508

Published: 2016

Journal Articles

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

Andy Rawstron, PhD, Claudia Fazi, PhD, Neus Villamor, MD PhD, Julio Delgado, MD PhD, Remi Letestu, MD PhD, Florence Cymbalista, MD, Carlos Palacio, Francesc Bosch, MD PhD, Ruth M De Tute, MSc, Stuart Liptrot, David O'Brien, FAMLs, Martin Spacek, MD, PhD, Johan Dobber, Arnon P. Kater, MD PhD, Peter C Gambell, David A Westerman, MBBS, FRACP, FRCPA, Asha Soosapilla, Stephen P. Mulligan, MBBS, PhD FRACP, FRCPA, Gerard Lozanski, MD, Ke Lin, PhD, Andrew R Pettitt, MRCP, PhD, Gabi Brachtl, Alexander Egle, MD, David W Williamson, PhD, Catherine M Sanders, PhD, Harlan Robins, PhD, Justin Boysen, Tait D. Shanafelt, MD, Curtis A. Hanson, MD, Jeffrey L. Jorgensen, MD PhD, William G. Wierda, MD PhD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, Laura Rassenti, PhD, H. Elizabeth Broome, MD, Thomas J. Kipps, MD PhD, Mathieu Hauwel, Iuri Marinov, Fiona E. Craig, MBBS, Nomdedeu Josep, Carol Moreno, MD, Olga Stehlikova, MSc., Michael Doubek, Sarka Pospisilova, Prof., Dr., PhD, Karl-Anton Kreuzer, MD, Michael Hallek, MD, Peter Hillmen, MBChB, PhD, Emili Montserrat, MD PhD, Paolo Ghia, MD

Blood (2014) 124 (21): 1976.

https://doi.org/10.1182/blood.V124.21.1976.1976

Published: 2014

Journal Articles

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

Sajitha Sachchithanantham, BSc,MBBS,MRCP,FRCPath,, Ruth M de Tute, Anna Baginska, Christopher Parrish, MD, Shameem Mahmood, MRCP. FRCPath, Andy Rawstron, PhD, Julian D Gillmore, MD FRCP, Helen J Lachmann, MD FRCP, Philip N Hawkins, Roger G Owen, MD, Ashutosh Wechalekar, Dr

Blood (2014) 124 (21): 2073.

https://doi.org/10.1182/blood.V124.21.2073.2073

Published: 2014

Journal Articles

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Ruth M de Tute, MSc, David A Cairns, PhD, Marie Fletcher, Roger G Owen, MD, Andy Rawstron, PhD, Sheila J.M. O'Connor, PhD, Cathy D. Williams, MBBS, MCRP, FRCPath, John A Snowden, MD, FRCP, FRCPath, J. D. Cavenagh, MD, MRCP, Christopher Parrish, MA, MB, BChir, MRCP, Treen Morris, Julia MB Brown, Gordon Cook, MD, PhD

Blood (2013) 122 (21): 3378.

https://doi.org/10.1182/blood.V122.21.3378.3378

Published: 2013

Journal Articles

Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL

Anna Vardi, Antonis Dagklis, Lydia Scarfò, Diane Jelinek, Darren Newton, Fiona Bennett, Julia Almeida, Arancha Rodriguez-Caballero, Sallie Allgood, Mark Lanasa, Agostino Cortelezzi, Ester Orlandi, Silvio Veronese, Marco Montillo, Andy Rawstron, Tait Shanafelt, Alberto Orfao, Kostas Stamatopoulos, Paolo Ghia

Blood (2013) 121 (22): 4521–4528.

https://doi.org/10.1182/blood-2012-12-471698

Published: 2013

Includes: Supplemental data

Journal Articles

What Numbers Don't Say: Immunogenetic Evidence Shows That High-Count MBL Resembles Rai 0 CLL While Low-Count MBL Does Not.

Anna Vardi, Antonis Dagklis, Lydia Scarfò, Diane F. Jelinek, PhD, Darren J Newton, Chi Doughty, PhD, Julia Almeida, Arancha Rodriguez-Caballero, Sallie D. Allgood, MS, Mark C. Lanasa, MD, PhD, Agostino Cortelezzi, MD, Ester M Orlandi, Silvio Veronese, Marco Montillo, MD, Andy Rawstron, PhD, Tait D. Shanafelt, MD, Alberto Orfao, Kostas Stamatopoulos, Paolo Ghia

Blood (2012) 120 (21): 2883.

https://doi.org/10.1182/blood.V120.21.2883.2883

Published: 2012

Journal Articles

Aberrant Expression of Neuronal Receptors in CLL: Potential Targets with Therapeutic Implications

Abraham M Varghese, Andy Rawstron, PhD, Gina M Doody, PhD, Darren J Newton, Reuben Tooze, PhD, Peter Hillmen, MBChB, PhD

Blood (2012) 120 (21): 3899.

https://doi.org/10.1182/blood.V120.21.3899.3899

Published: 2012

Journal Articles

Identifying Phenotypically and Clinically Distinct Entities within the Spectrum of Marginal Zone Lymphoma and Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia

Ruth M de Tute, Eve Roman, Andrew Jack, PhD, MB, Roger G Owen, MD, Andy Rawstron, PhD

Blood (2011) 118 (21): 2652.

https://doi.org/10.1182/blood.V118.21.2652.2652

Published: 2011

Journal Articles

In Vitro Generation of “Long-Lived” Human Plasma Cells

Sophie Stephenson, Msc, Mario Cocco, PhD, Ruth deTute, Msc, Andy Rawstron, PhD, Gina Doody, PhD, Reuben Tooze, PhD

Blood (2011) 118 (21): 2187.

https://doi.org/10.1182/blood.V118.21.2187.2187

Published: 2011

NARROW

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Telomere Length Predicts for Outcome to FCR Chemoimmunotherapy in CLL

Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure

Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study

Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy

Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide

BCR Unresponsiveness and 13q14 Duplication Underpin Spontaneous Disease Regression in Chronic Lymphocytic Leukemia

Obinutuzumab As Consolidation after Chemo-Immunotherapy Is Highly Effective in Achieving MRD Clearance from Bone Marrow and Peripheral Blood- Initial Results of UK NCRI Phase II/III Galactic Trial

The Bloodwise TAP Calibre Feasibility Study to Assess the Mechanism of Action of Idelalisib in B-Cell Receptor Pathway (BCR) Inhibition in Chronic Lymphocytic Leukaemia (CLL)

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study

The Prognostic Significance of Phenotypically ‘Normal’ Plasma Cells in Chemotherapy Treated AL Patients with Underlying MGUS and Multiple Myeloma

The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL

What Numbers Don't Say: Immunogenetic Evidence Shows That High-Count MBL Resembles Rai 0 CLL While Low-Count MBL Does Not.

Aberrant Expression of Neuronal Receptors in CLL: Potential Targets with Therapeutic Implications

Identifying Phenotypically and Clinically Distinct Entities within the Spectrum of Marginal Zone Lymphoma and Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia

In Vitro Generation of “Long-Lived” Human Plasma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only